Display options
Cite
Ricci AD, Rizzo A, Mollica V, et al. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data. Anticancer Drugs. 2021;doi: 10.1097/CAD.0000000000001200.
Ricci, A. D., Rizzo, A., Mollica, V., Schiavina, R., Fiorentino, M., Brunocilla, E., Ardizzoni, A., & Massari, F. (2021). Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data. Anti-cancer drugs, . https://doi.org/10.1097/CAD.0000000000001200
Ricci, Angela Dalia, et al. "Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data." Anti-cancer drugs vol. (2021). doi: https://doi.org/10.1097/CAD.0000000000001200
Ricci AD, Rizzo A, Mollica V, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data. Anticancer Drugs. 2021 Aug 11; doi: 10.1097/CAD.0000000000001200. Epub 2021 Aug 11. PMID: 34387596.
Copy Download .nbib Format: NLM
Share it on

Anticancer Drugs. 2021 Aug 11; doi: 10.1097/CAD.0000000000001200. Epub 2021 Aug 11.

Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data.

Anti-cancer drugs

Angela Dalia Ricci, Alessandro Rizzo, Veronica Mollica, Riccardo Schiavina, Michelangelo Fiorentino, Eugenio Brunocilla, Andrea Ardizzoni, Francesco Massari

Affiliations

  1. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Urology, S-Orsola-Malpighi Hospital Department of Pathology, School of Medicine, University of Bologna, Bologna, Italy.

PMID: 34387596 DOI: 10.1097/CAD.0000000000001200

Abstract

AIM: We performed a systematic review and meta-analysis to evaluate the role of platinum-based adjuvant chemotherapy (AC) in upper tract urothelial carcinoma.

MATERIALS METHODS: Eligible studies were identified using Pubmed/Medline, Cochrane library, Embase and meeting abstracts. Outcomes of interest included: overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS).

RESULTS: Platinum-based AC was associated with improved DFS, while the benefit in OS and CSS was not statistically significant compared to observation. Conversely, platinum-based AC showed a modest OS benefit in an analysis combing multivariable HRs with estimated HRs from Kaplan-Meier curves.

CONCLUSION: Our results suggest that platinum-based AC is associated with improved DFS and a modest OS benefit in patients with locally advanced urothelial carcinomas.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Publication Types